Journal of the National Cancer Institute Advance Access originally published online on August 26, 2008
JNCI Journal of the National Cancer Institute 2008 100(17):1196-1199; doi:10.1093/jnci/djn318
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© Oxford University Press 2008.
NEWS |
Leaders Worry That U.S. Is Losing Edge on Cancer Clinical Trials
| The first 150 words of the full text of this article appear below. |
In today's global research climate, it is increasingly true that cancer drugs are being tested around the world, reaching more and more of the populations who might benefit from their use.
But whereas many see this as good news, researchers in the U.S. are also beginning to feel a downside to this trend. The bad news, many say, is that American scientists are less engaged in this effort than they would like to be. Because of clinical trial costs and regulations, among other variables, NIH-funded trials don’t often include international patients, and these same factors also mean that it is increasingly unlikely that U.S. patients are included in international studies that originate in other countries, whether they are conducted by academic or pharmaceutical industry researchers.
That lament was prominent at this year's American Society of Clinical Oncology (ASCO) annual meeting. In the first press briefing, outgoing ASCO president Nancy Davidson,
Budget Constraints
Global Inequity in Research
EU Researchers Face Hurdles Too
Industry Has Few Incentives To Run Clinical Trials in the U.S., Researchers Say